Main outcome profile (intent to treat) in groups treated with prophylactic agents for acute mountain sickness. Values are numbers (percentages) unless stated otherwise

Variables
All participants (n=487)
Placebo group (n=119)
Acetazolamide group (n=118)
Odds ratio (95% Cl)^*
Ginkgo group (n=124)
Odds ratio (95% Cl)^*
Combined acetazolamide and ginkgo group (n=126)
Odds ratio (95% Cl)^*

Incidence of acute mountain sickness
115 (24)
40 (34)
14 (12)
3.76 (1.91 to 7.39)
43 (35)
0.95 (0.56 to 1.62)
18 (14)
3.04 (1.62 to 5.69)

Severe acute mountain sickness
58 (12)
22 (18)
4 (3)
6.46 (2.15 to 19.40)
23 (18)
1.00 (0.52 to 1.90)
9 (7)
2.95 (1.30 to 6.70)

Headache incidence
197 (40)
63 (53)
23 (19)
4.77 (2.70 to 8.44)
72 (58)
0.75 (0.47 to 1.22)
39 (31)
2.62 (1.58 to 4.35)

Severe headache
46 (9)
16 (13)
2 (2)
9.01 (2.02 to 40.13)
24 (19)
0.65 (0.32 to 1.29)
4 (3)
4.74 (1.54 to 14.62)

Mean endpoint oxygen saturation (%)^¶
82.3
82.1
83.7
P=0.01
79.5
P<0.01
83.9
P<0.01

Decrease in oxygen saturation from baseline^¶
3.0
3.8
1.7
P<0.01
5.2
P=0.04
1.5
P<0.01

Non-compliant^**
25 (5)
6 (5)
5 (4)
0.75 (0.75 to 2.10)
4 (3)
1.49 (0.46 to 4.76)
10 (8)
0.59 (0.22 to 1.56)